EA201691808A8 - Кортикостероидные композиции для местного применения - Google Patents

Кортикостероидные композиции для местного применения

Info

Publication number
EA201691808A8
EA201691808A8 EA201691808A EA201691808A EA201691808A8 EA 201691808 A8 EA201691808 A8 EA 201691808A8 EA 201691808 A EA201691808 A EA 201691808A EA 201691808 A EA201691808 A EA 201691808A EA 201691808 A8 EA201691808 A8 EA 201691808A8
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
local application
corticosteroid compositions
corticosteroid
disorders
Prior art date
Application number
EA201691808A
Other languages
English (en)
Other versions
EA201691808A1 (ru
Inventor
Сатиш Кандавилли
Приядаршани Сахукар
Франклин ОКУМУ
Original Assignee
Промиус Фарма, Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Промиус Фарма, Ллк filed Critical Промиус Фарма, Ллк
Publication of EA201691808A1 publication Critical patent/EA201691808A1/ru
Publication of EA201691808A8 publication Critical patent/EA201691808A8/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Композиции для местного введения активного агента, содержащие кортикостероид и жирный спирт в качестве интенсификатора проникновения через кожу, в форме распыляемых композиций для местного применения. Способы получения таких композиций и способы их использования для лечения кожных заболеваний или нарушений, таких как псориаз, дерматозы и другие сопутствующие кожные заболевания или нарушения.
EA201691808A 2014-03-11 2015-03-11 Кортикостероидные композиции для местного применения EA201691808A8 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461951165P 2014-03-11 2014-03-11
PCT/US2015/020031 WO2015138650A1 (en) 2014-03-11 2015-03-11 Topical corticosteroid compositions

Publications (2)

Publication Number Publication Date
EA201691808A1 EA201691808A1 (ru) 2017-02-28
EA201691808A8 true EA201691808A8 (ru) 2017-04-28

Family

ID=52727460

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201691808A EA201691808A8 (ru) 2014-03-11 2015-03-11 Кортикостероидные композиции для местного применения
EA201692334A EA201692334A1 (ru) 2014-03-11 2015-09-09 Кортикостероидные композиции для местного применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201692334A EA201692334A1 (ru) 2014-03-11 2015-09-09 Кортикостероидные композиции для местного применения

Country Status (13)

Country Link
US (4) US20150258119A1 (ru)
EP (2) EP3116473B1 (ru)
JP (2) JP6487949B2 (ru)
KR (2) KR101930244B1 (ru)
CN (1) CN106659682B (ru)
AU (2) AU2015229403B2 (ru)
BR (1) BR112016021023A2 (ru)
CA (2) CA2945943C (ru)
EA (2) EA201691808A8 (ru)
ES (1) ES2857602T3 (ru)
MX (2) MX2016011842A (ru)
WO (2) WO2015138650A1 (ru)
ZA (1) ZA201606704B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2473161T3 (en) 2009-08-31 2017-09-11 Dr Reddys Laboratories Ltd TOPICAL FORMULATIONS INCLUDING A STEROID
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
WO2017091168A1 (en) * 2015-11-28 2017-06-01 Pharmacti̇ve İlaç San. Ve Ti̇c. A.Ş. A topical spray comprising isoconazole nitrate and difluocortolone valerate
EP3405174A4 (en) * 2016-01-12 2019-10-30 Nortic Holdings Inc. FORMATION OF BETAETHASONE FOR ORAL SPRAY AND USE THEREOF FOR THE TREATMENT OF ATAXIA
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
US20180028766A1 (en) * 2016-07-27 2018-02-01 Sun Pharmaceutical Industries Limited Touch-free topical spray of halobetasol
EP3515422A1 (en) 2016-09-21 2019-07-31 Avexxin AS Pharmaceutical composition
US10543177B2 (en) 2017-04-11 2020-01-28 Kevin Mrohs Composition and method for treating skin conditions
EP3752992A4 (en) 2018-02-19 2021-12-08 InVue Security Products, Inc. GOODS SECURING SYSTEM WITH INDUCTIVE CHARGING
CN113453670A (zh) * 2018-09-28 2021-09-28 乔·斯图丁 类固醇和大分子的透孔递送
JP7412292B2 (ja) * 2019-07-10 2024-01-12 積水化学工業株式会社 製剤
WO2021080527A1 (en) * 2019-10-24 2021-04-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. Topical pharmaceutical compositions containing difluocortolone and isoconazole
CN115103666A (zh) * 2020-02-11 2022-09-23 塔罗制药工业有限公司 包含去羟米松和他扎罗汀的组合物
US11382863B2 (en) * 2020-03-04 2022-07-12 Somerset Therapeutics Llc Injectable suspension comprising an insoluble corticosteroid and a soluble corticosteroid
CN113092601B (zh) * 2021-03-02 2022-12-20 苏州市药品检验检测研究中心 一种化妆品中倍他米松17-丙酸酯及倍他米松21-丙酸酯的检测方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892856A (en) 1974-04-10 1975-07-01 Squibb & Sons Inc Topical steroid formulation
US3934013A (en) 1975-02-21 1976-01-20 Syntex (U.S.A.) Inc. Pharmaceutical composition
US4343798A (en) 1981-06-23 1982-08-10 The Procter & Gamble Company Topical antimicrobial anti-inflammatory compositions
US4552872A (en) * 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
AU6974191A (en) * 1989-12-20 1991-07-18 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
IT1247529B (it) 1991-04-24 1994-12-17 Poli Ind Chimica Spa Composizioni farmaceutiche in forma di schiuma per somministrazione intravaginale, cutanea e orale
CA2201358C (en) 1994-09-30 2004-06-08 Jurgen Regenold Pharmaceutical composition
GB9504265D0 (en) 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
IL152486A0 (en) * 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20080206161A1 (en) * 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US7820145B2 (en) * 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
ZA200507018B (en) * 2003-12-16 2008-02-27 Foamix Ltd Oleaginous pharmaceutical and cosmetic foam
CN101048136B (zh) * 2004-08-31 2011-06-22 施蒂福研究澳大利亚股份有限公司 微乳化和亚微米乳化方法和组合物
CA2578594C (en) * 2004-08-31 2012-04-17 Connetics Australia Pty Ltd Microemulsion & sub-micron emulsion process & compositions
US20060246098A1 (en) * 2005-03-16 2006-11-02 Srinivasa Rao Stable aqueous-based emulsion formulation comprising urea and salicylic acid and method of using same
DK1885373T3 (en) 2005-04-25 2015-08-10 Dow Pharmaceutical Sciences Use of a spray formulation of clobetasol for the treatment of psoriasis
GB2443162B (en) 2006-10-28 2011-02-09 Nupharm Lab Ltd Betamethasone spray
DK2473161T3 (en) * 2009-08-31 2017-09-11 Dr Reddys Laboratories Ltd TOPICAL FORMULATIONS INCLUDING A STEROID
CA2776366C (en) * 2009-10-02 2017-07-18 Foamix Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
NL2004437C2 (en) * 2010-03-19 2011-09-20 Forte Iq B V Spray-pumpable comprising composition suitable for topical skin application.
CA2802041A1 (en) * 2010-06-11 2011-12-15 Precision Dermatology, Inc. High oil-content emollient aerosol foam compositions
SG11201500988VA (en) * 2012-08-10 2015-04-29 Asahi Glass Co Ltd Method for producing carbonate compound and method for producing aromatic polycarbonate
JP6473134B2 (ja) * 2013-03-15 2019-02-20 メディシス ファーマシューティカル コーポレイション フルニソリドの局所用組成物および治療方法
US10111956B2 (en) * 2013-06-03 2018-10-30 Tolmar, Inc. Corticosteroid compositions

Also Published As

Publication number Publication date
CA2945943A1 (en) 2015-09-17
AU2015229403A1 (en) 2016-10-27
AU2015385750B2 (en) 2019-01-31
JP2017530974A (ja) 2017-10-19
CN106659682A (zh) 2017-05-10
CA2945943C (en) 2020-10-27
EA201692334A1 (ru) 2018-02-28
BR112016021023A8 (pt) 2018-01-30
EA201691808A1 (ru) 2017-02-28
KR101930246B1 (ko) 2018-12-18
CN106659682B (zh) 2020-12-29
EP3116473B1 (en) 2020-12-30
AU2015229403B2 (en) 2019-05-02
EP3116473A1 (en) 2017-01-18
WO2015138650A1 (en) 2015-09-17
KR20170023791A (ko) 2017-03-06
ES2857602T3 (es) 2021-09-29
MX2016011842A (es) 2017-02-02
KR20160144377A (ko) 2016-12-16
JP2017508802A (ja) 2017-03-30
US20200230155A1 (en) 2020-07-23
AU2015385750A1 (en) 2016-10-27
MX2016011841A (es) 2017-02-02
WO2016144381A1 (en) 2016-09-15
US20160030450A1 (en) 2016-02-04
CA2946201C (en) 2020-10-27
JP6487949B2 (ja) 2019-03-20
CA2946201A1 (en) 2016-09-15
EP3197432A1 (en) 2017-08-02
KR101930244B1 (ko) 2018-12-18
US20180250312A1 (en) 2018-09-06
JP6535735B2 (ja) 2019-06-26
BR112016021023A2 (pt) 2021-09-14
EP3197432A4 (en) 2018-10-10
ZA201606704B (en) 2019-07-31
US20150258119A1 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
EA201692334A1 (ru) Кортикостероидные композиции для местного применения
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX2021001439A (es) Composiciones y metodos para el tratamiento de la disfuncion de la glandula de meibomio.
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
GT201500294A (es) Compuestos de biaril-amida como inhibidores de cinasa
CO2018001375A2 (es) Composiciones de retinoides tópicos
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
PH12017500239A1 (en) Abiraterone acetate formulation and methods of use
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MY193312A (en) Topical formulation for promoting wound healing
EA201690323A1 (ru) Способы лечения заболеваний уха у детей
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
GT201400146A (es) Composiciones farmacéuticas tópicas que comprenden bexaroteno y corticosteroides
BR112018012349A2 (pt) composição farmacêutica espumante, composição espumante de armazenamento estável e método para tratar um indivíduo com, ou em risco de ter, uma doença, condição ou distúrbio da pele
PH12020500472A1 (en) Autotaxin inhibitor compounds
EA201991866A1 (ru) Комбинированная терапия
MX2018002449A (es) Formulaciones de liberacion retardada, metodos de fabricacion y uso de las mismas.
IN2014DE00648A (ru)
UA112489C2 (uk) Спосіб лікування вугрової хвороби шкіри обличчя та спини за індріксоном